In United States, the year-to-date performance of SPDR S&P Biotech Index (NYSEARCA:XBI) stands at 33% year to date, reflecting that investment dollars are willingly flowing into the biotech sector.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) jumped about 27% on Friday after signing drug development deal with Pfizer Inc. (NYSE:PFE). The stock is currently trading 24.35% up its SMA 50. In the last trading session, its price moved -8.94% below its 200 day moving average, changing hands as low as $6.21 per share.

The worst hit in its 52 week range is $3.86 per share, with $13.50 being the 52 week best price, which compares with a latest closing price of $7.01. The Beta of this stock is 1.51.

On the flip side, the share price of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) lost -22.22% during trading yesterday after a federal advisory panel voted 8 to 5 against the approval of rintatolimod to be used for the treatment of chronic fatigue syndrome, ending the day at $0.280.

At that price, the company has a market cap of $42.28 million. The stock has a 52 week worst hit of $0.19 and a 52 week high of $1.10. The P/S ratio is 211.41 and P/B ratio 1.17. The beta value is 1.22. HEB’s RSI amounts to 22.10.

The market value of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is $1.88 billion. It has 255 people in workforce, over the last 12 months has generated revenue of $27.73 million and has earnings of -$90.70 million. The firm’s operating margin is -221.81 percent and net profit margin -316.94 percent. The latest closing price of its shares moved down -1.81% from the 50-day moving average.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) continued to extend fall after Fabry drug failed late-stage study. For this company, a return on equity of -83.55 percent has been realized due to the financial position. Last twelve months per-share profit reached a value of -$1.13. The stock closed at $2.76, down -0.30 points or -9.80% from previous close and at a distance of -48.96% from 20-day simple moving average.